New York Cardiovascular Symposium

FRIDAY, DECEMBER 6 -SUNDAY, DECEMBER 8, 2019

New York Hilton - Midtown





THURSDAY, DECEMBER 5

2:30 p.m. Registration - Rhinelander North, Level 2

4:30 p.m. 7:00 p.m. Pre-Conference Session: *The Power of Real World Evidence* - Rhinelander South, Level 2

FRIDAY, DECEMBER 6

Registration - Rhinelander North, Level 2

6:00 a.m. 7:45 a.m. Visit the Exhibits and Breakfast - Americas Hall, Level 3

7:45 a.m. - 8:00 a.m.

Introductions

Timothy W. Attebery, DSc, MBA, FACHE (by video)
Chief Executive Officer, American College of Cardiology

Richard J. Kovacs, MD, FACC *(by video)*President, American College of Cardiology

Norma Keller, MD, FACC

President, New York State Chapter, American College of

Cardiology

8:00 a.m. - 9:35 a.m.

CARDIOVASCULAR & CORONARY ARTERY DISEASE — CHALLENGES IN 2019

Session I: Evolving New Frontiers Ready for Practice

Chair: Dr. Daniele Andreini

8:00 a.m.	8:25 a.m.	Noninvasive Imaging (3D-US, PET, MRI) & Genetic Stratification (50 Variants): Predicting Progression of CVD in Over 1,000 Subjects	Dr. Valentin Fuster
8:25 a.m.	8:45 a.m.	CTA Imaging in the Full Assessment of Coronary Disease: Noninvasive Approach to Plaque Anatomy, Ischemia & Microcirculation	Dr. Daniele Andreini
8:45 a.m.	9:05 a.m.	Primary Results of the ISCHEMIA Trial	Dr. Judith Hochman
9:05 a.m.	9:35 a.m.	Panel Discussion	Drs. Andreini, Fuster & Hochman
9:35 a.m.	9:55 a.m.	Visit the Exhibits and Coffee Break - Americas Hall, Level 3	

9:55 a.m. - 11:45 a.m.

Session II: Acute Coronary Syndrome Complexities

Chair: Dr. Jonathan Halperin

9:55 a.m. 10:15 a.m. STEMI 1- PCI Culprit Lesion vs Complete Revascularization: With Dr. Deepak Bhatt

vs Without Cardiogenic Shock

10:15 a.m.	10:35 a.m.	STEMI 2- Cardiogenic Shock and Revascularization Strategies	Dr. Sripal Bangalore
10:35 a.m.	10:55 a.m.	STEMI vs. NSTEMI vs. STABLE CAD - Optimal Antithrombotics & Timing. DAPT - Stent, Complexity, Comorbidities - and NOACs Role	Dr. Roxana Mehran
10:55 a.m.	11:15 a.m.	STEMI vs. NSTEMI vs. STABLE CAD - Evolving Antithrombotics & Safety: APT &/or NOAC - CAD Stent & AF, CAD Stent & No Stent, VHD / PHV & AF	Dr. Jonathan Halperin
11:15 a.m.	11:45 a.m.	Panel Discussion	Drs. Bangalore, Bhatt, Halperin & Mehran
11:45 a.m.	12:45 p.m.	Visit the Exhibits and Lunch - Americas Hall, Level 3	
12:45 p.m. – 2:55 Session III: Syste Chair: Dr. Patrick	mic Arterial Disease -	– Chronic Coronary Disease, Stroke and Pulmonary Embolism	
12:45 p.m.	1:10 p.m.	Chest Pain Evaluation - Possible vs Probable CAD Evaluation: CAC vs. Stress Test vs. CT Angio vs. Coronary Angiogram	Dr. Jeroen J. Bax
1:10 p.m.	1:35 p.m.	Managing Steps - Clinical, Anatomy, LV, Ischemia, Plaque, Microcirculation: Role of PCI vs. CABG vs. OMT	Dr. Valentin Fuster
	2:00 p.m.	Complexities of Acute Stroke and Chronic Carotid Artery Stenosis: Two Entities With Novel Therapeutic Approaches	Dr. Priyank Khandelwal
2:00 p.m.	2:25 p.m.	Pulmonary Emboli - Diagnosis Based on Suspicion: Management Based on the Acute Severity and Degree of Chronic PH	Dr. Cecilia Becattini
2:25 p.m.	2:55 p.m.	Panel Discussion	Drs. Bax, Becattini, Khandelwal & Fuster
2:55 p.m.	3:15 p.m.	Visit the Exhibits and Coffee Break - Americas Hall, Level 3	
3:15p.m. – 6:00 Session IV: Trenc Chair: Dr. Sidney		Approaching Prevention — Health Factors	
3:15 p.m.		JACC Seminar: Four Challenges To Enhance Eight Health Factors 1. Pathophysiological Effects 2. Machanistic / Triggering Factors 2. Bala of Browntine Action 4	Dr. Valentin
	Smith		
3:15 p.m.	Smith	 Pathophysiological Effects Mechanistic/Triggering Factors 3. Role of Preventive Action 4. 	Valentin
3:15 p.m. 3:35 p.m.	Smith 3:35 p.m.	 Pathophysiological Effects Mechanistic/Triggering Factors 3. Role of Preventive Action 4. Competencies for Training 	Valentin Fuster
3:15 p.m. 3:35 p.m. 3:50 p.m.	3:35 p.m. 3:50 p.m.	 Pathophysiological Effects Mechanistic/Triggering Factors 3. Role of Preventive Action 4. Competencies for Training Healthy Weight 	Valentin Fuster Dr. Carl Lavie
3:15 p.m. 3:35 p.m. 3:50 p.m. 4:05 p.m.	3:35 p.m. 3:50 p.m. 4:05 p.m.	 Pathophysiological Effects Mechanistic/Triggering Factors 3. Role of Preventive Action 4. Competencies for Training Healthy Weight Nutrition and Diet 	Valentin Fuster Dr. Carl Lavie Dr. Robert Rosenson
3:15 p.m. 3:35 p.m. 3:50 p.m. 4:05 p.m. 4:20 p.m.	3:35 p.m. 3:50 p.m. 4:05 p.m. 4:20 p.m.	 Pathophysiological Effects Mechanistic/Triggering Factors 3. Role of Preventive Action 4. Competencies for Training Healthy Weight Nutrition and Diet Physical Activity 	Valentin Fuster Dr. Carl Lavie Dr. Robert Rosenson Dr. Carl Lavie
	3:35 p.m. 3:50 p.m. 4:05 p.m. 4:20 p.m. 4:35 p.m.	 Pathophysiological Effects Mechanistic/Triggering Factors 3. Role of Preventive Action 4. Competencies for Training Healthy Weight Nutrition and Diet Physical Activity Tobacco Free 	Valentin Fuster Dr. Carl Lavie Dr. Robert Rosenson Dr. Carl Lavie Dr. Nancy Rigotti

5:20 p.m.	5:35 p.m.	Psychological Health	Dr. Patrick O'Gara
5:35 p.m.	6:00 p.m.	Panel Discussion	Drs. Fuster, Lavie, O'Gara, Rigotti Rosenson & Smith
5:00 p.m. Adjourn			
SATURDAY, DEC	EMBER 7		
6:00 a.m.	8:00 a.m.	Registration - Rhinelander North, Level 2 Visit the Exhibits and Breakfast - Americas Hall, Level 3	
	NARY AND ELECTRICA ardial Disease and He	AL FAILURE 2019 eart Failure; Basis for Management	
8:00 a.m.	8:20 a.m.	Evolving Imaging (MRI, PET) as Diagnostic & Prognostic Tools For 7 Myocardial Diseases - Myocarditis, Dilated CM, Hypertrophic CM, Noncompaction LV, Amyloid CM, Sarcoid & Takotsubo	Dr. Y. S. Chandrashekhar
8:20 a.m.	8:35 a.m.	Evolving Clinical Genetics & Omics in Myocardial Disease: Which or What Subgroup of the 7 Entities Should Be Gene Tested	Dr. Amy Kontorovich
8:35 a.m.	9:00 a.m.	Evolving Understanding of HFrEF vs HFpEF vs HFiEF (i=Intermediate) Different Biological Phenotypes and Evolving Therapeutic Options	Dr. G. William Dec
9:00 a.m.	9:20 a.m.	Evolving Therapeutic Approaches to 3 Challenging Cardiomyopathies: Myocarditis, Takotsubo and AL/TTR Amyloid	Dr. Mathew Maurer
9:20 a.m.	9:40 a.m.	LVADs - The 2 Upcoming Challenges 1. Indications: not too Late, Not too Early, since Risks are High 2. New Biocompatible Devices, Equal to Transplant Survival?	Dr. Mandeep Mehra
9:40 a.m.	10:10 a.m.	Panel Discussion	Drs. Chandrashekhar, Dec, Kontorovich, Maurer & Mehra
10:10 a.m.	10:30 a.m.	Visit the Exhibits and Coffee Break - Americas Hall, Level 3	
10:30 a.m. – 12: Session VI: Rhytl		nporary and Future Topics of Focus	
Chair, Dr. Francis			
10:30 a.m.	10:55 a.m.	Atrial Fibrillation 2019 - The 14 Non-Ablation Clinical Challenges: Quality of Life & Preventing Stroke	Dr. Valentin Fuster
10:55 a.m.	11:15 a.m.	Atrial Fibrillation: Catheter Ablation - 4 Questions: Who?, When ?, How?, Results? (CABANA & Others)	Dr. Francis Marchlinski
11:15 a.m.	11:30 a.m.	Left Atrial Appendage Closure - 4 Questions: Who?, When?, How?, Results?	Dr. Vivek Reddy
11:30 a.m.	11:50 a.m.	Ventricular Tachycardia: Catheter Ablation - 4 Questions Who?, When ?, How?, Results?	Dr. Francis Marchlinski

11:50 a.m.	12:10 p.m.	Follow Up of The Three Recent Device Therapeutic Approaches: CRTs Strict Indications, Subcutaneous ICDs, Leadless Pacemakers	Dr. Jagmeet Singh
12:10 p.m.	12:30 p.m.	Panel Discussion	Drs. Fuster, Marchlinski, Reddy & Singh
12:30 p.m.	2:00 p.m.	Visit the Exhibits and Lunch - Americas Hall, Level 3	
2:00 p.m. – 3:30		alvo Disease and Acute	
Chair, Dr. Rick N		Ilve Disease and Aorta	
2:00 p.m.	2:10 p.m.	Aortic Valvular Stenosis: 3 Diagnostic and Management Challenges: Congenital vs Senile; Asymptomatic vs Symptomatic; Low Flow/Low Gradient: CM 2ary to AS vs. Dilated vs Restrictive	Dr. Robert Bonow
2:10 p.m.	2:30 p.m.	Discussants	Drs. Nishimura, O'Gara, Sharma & Bax
2:30 p.m.	2:40 p.m.	Aortic Regurgitation 3 Diagnostic and Management Challenges: Associated or not Dilatation of the Aorta Asymptomatic vs Symptomatic EF Low/Intermediate vs Normal	Dr. Rick Nishimura
2:40 p.m.	3:00 p.m.	Discussants	Drs. Bonow, O'Gara, Sharma & Bax
3:00 p.m.	3:20 p.m.	The Dilated Thoracic & Abdominal Aorta and Complicating Dissection: Evolving Understanding of the Basic Biology & Management	Dr. Valentin Fuster
3:20 p.m.	3:30 p.m.	Discussants	Drs. Bax & El-Hamamsy
3:30 p.m.	3:50 p.m.	Visit the Exhibits and Coffee Break - Americas Hall, Level 3	
3:50 p.m. – 5:30 Session VIII: Ma Chair, Dr. Jeroer	nagement of Mitral Ro	egurgitation, Tricuspide Regurgitation and Hypertrophic Cardiomyopa	athy
3:50 p.m.	4:00 p.m.	Mitral Regurgitation: 3 Diagnostic and Management Challenges: Primary vs Secondary; Asymptomatic vs Symptomatic; EF Low/Intermediate vs Normal	Dr. Gregg Stone
4:00 p.m.	4:20 p.m.	Discussants	Drs. Bonow, O'Gara, Sharma & Bax
4:20 p.m.	4:30 p.m.	Tricuspid Regurgitation: 3 Diagnostic and Management Challenges: Primary vs Secondary to Pulmonary Hypertension; Residual from Previous Left Sided Valvular Surgery or not; Symptomatic with RVEF Low/Intermediate vs Normal	Dr. Josep Rodes-Cabau
4:30 p.m.	4:50 p.m.	Discussants	Drs. Bonow, O'Gara, Sharma & Bax
4:50 p.m.	5:10 p.m.	Hypertrophic Cardiomyopathy - 4 Challenging Questions: Genetics/Acquired; Myectomy/3Types; Natural Hx/ICD; Apical/Aneurysm	Dr. Rick Nishimura

5:30 p.m. Adjourn			
SUNDAY, DECEN	1BER 8	Registration - Rhinelander North, Level 2	
6:00 a.m.	8:00 a.m.	Breakfast - Americas Hall, Level 3	
		breaklast - Americas nail, Level 5	
	: THE 9 HIGHLIGHTS (slational Progress on	OF PROGRESS IN 2019 Genetics, Cellular and Matrix Biology	
8:00 a.m.	8:20 a.m.	Part 1. Translational Progress in Genetic Medicine: From Gene Editing in Rhythm Disorders to iPCS in E-Cigarettes Dangers	Dr. Joseph Wu
8:20 a.m.	8:40 a.m.	Part 2. Translational Progress in Cell Regeneration & Degeneration: Clonal Hematopoiesis: A Potent, Common, and Newly Recognized Cardiovascular Risk Factor	Dr. Peter Libby
8:40 a.m.	9:00 a.m.	Part 3. Translational Progress in Extracellular Matrix: Defensive Remodeling vs Therapeutic Lysis	Dr. Jason Kovacic
9:00 a.m. – 10:0 Session X: Novel Chair, Dr. Valent	ties on Diagnostic &	Therapeutic Strategies	
9:00 a.m.	9:20 a.m.	Part 1. Evolving 18 F Fluoride PET - Clinical and Research Applications: Aortic Valvular Stenosis, Heart & Vascular Macrophage Infiltration	Dr. Marc Dweck
9:20 a.m.	9:40 a.m.	Part 2. Evolving Cardiac MRI - Clinical and Research Applications: Post Myocardial Infarction, Early Chemotherapy Toxicity	Dr. Borja Ibanez
9:40 a.m.	10:00 a.m.	Part 3. Evolving Diagnostic Tools - Evaluation of the Microcirculation: The Ignored Frequent Microvascular Syndromes	Dr. Viviany Taqueti
10:00 a.m.	10:20 a.m.	Coffee Break - Promenade, Level 3	
10:20 a.m. – 11 Session XI: Aimir Chair, Dr. Valent	ng at the Future of M	edicine	
10:20 a.m.	10:40 a.m.	Part 1. The Future of Health Education Starting at Pre-School: Approach in 50,000 Children, at Short, Middle and Long Term	Dr. Valentin Fuster
10:40 a.m.	11:00 a.m.	Part 2. Cognitive Impairment and Dementia in the Elderly: Vascular, Alzheimer's & Combination of Both	Dr. Rebecca Gottesman
11:00 a.m.	11:30 a.m.	PAUL DUDLEY WHITE KEYNOTE 2019 Part 3. The Future of Residual Risk Factors to Be Addressed After Cholesterol Management	Dr. Paul Ridker
11:30 a.m. Adjourn			
As of 11/06/19; Subiect to change			